Novel multivalent design of a monoclonal antibody improves binding strength to soluble aggregates of amyloid beta

ConclusionWe provide a new antibody design with increased valency to promote binding avidity to an enhanced range of sizes of A β aggregates. This approach should be general and work for any aggregated protein or repetitive target.
Source: Translational Neurodegeneration - Category: Neurology Source Type: research